-
公开(公告)号:US20080161297A1
公开(公告)日:2008-07-03
申请号:US11856740
申请日:2007-09-18
Applicant: Todd Bosanac , John David Ginn , Eugene Richard Hickey , Thomas Martin Kirrane , Weimin Liu , Anthony S. Prokopowicz , Sabine K. Schlyer , Cheng-Kon Shih , Roger John Snow , Michael Robert Turner , Frank Wu , Erick Richard Young
Inventor: Todd Bosanac , John David Ginn , Eugene Richard Hickey , Thomas Martin Kirrane , Weimin Liu , Anthony S. Prokopowicz , Sabine K. Schlyer , Cheng-Kon Shih , Roger John Snow , Michael Robert Turner , Frank Wu , Erick Richard Young
IPC: A61K31/4725 , A61P9/00 , A61P13/00 , A61P15/10 , A61P27/06 , A61P11/06 , A61K31/517 , A61K31/5377 , A61K31/496 , C07D239/88 , C07D217/24 , C07D401/02 , C07D417/02 , A61K31/541 , A61K31/472
CPC classification number: A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/541 , C07D217/24 , C07D239/88 , C07D239/90 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D487/08
Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Abstract translation: 公开了用作Rho激酶抑制剂的新型取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物,并用于治疗通过Rho激酶(包括心血管疾病)的活性介导或维持的多种疾病和病症 包含这些化合物的药物组合物,使用这些化合物的方法和制备这些化合物的方法。
-
公开(公告)号:US08809326B2
公开(公告)日:2014-08-19
申请号:US11856740
申请日:2007-09-18
Applicant: Todd Bosanac , John David Ginn , Eugene Richard Hickey , Thomas Martin Kirrane, Jr. , Weimin Liu , Anthony S. Prokopowicz , Sabine K. Schlyer , Cheng-Kon Shih , Roger John Snow , Michael Robert Turner , Frank Wu , Erick Richard Young
Inventor: Todd Bosanac , John David Ginn , Eugene Richard Hickey , Thomas Martin Kirrane, Jr. , Weimin Liu , Anthony S. Prokopowicz , Sabine K. Schlyer , Cheng-Kon Shih , Roger John Snow , Michael Robert Turner , Frank Wu , Erick Richard Young
IPC: A61P9/00 , A61P13/00 , A61P15/10 , A61P27/06 , A61P11/06 , C07D217/24 , C07D401/02 , C07D417/02 , C07D239/88 , A61K31/541 , A61K31/4725 , A61K31/472 , C07D239/90 , C07D487/08 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , A61K31/517 , A61K31/5377 , A61K31/496
CPC classification number: A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/541 , C07D217/24 , C07D239/88 , C07D239/90 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D487/08
Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Abstract translation: 公开了用作Rho激酶抑制剂的新型取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物,并用于治疗通过Rho激酶(包括心血管疾病)的活性介导或维持的多种疾病和病症 包含这些化合物的药物组合物,使用这些化合物的方法和制备这些化合物的方法。
-